Limited time75% off all plans
Get the app

Growth hormone disorders

On this page

GH Physiology - The Growth Blueprint

  • Secretion: Pulsatile, with largest peak during deep sleep (Stage N3).
  • Actions (Dual Role):
    • Direct: Anti-insulin effects (↑ lipolysis, ↑ blood glucose).
    • Indirect: Via IGF-1 from liver; mediates linear growth (epiphyseal plates) and protein synthesis.

⭐ Screening for GH disorders relies on IGF-1 levels, not random GH, due to GH's pulsatile release versus IGF-1's stable, longer half-life.

Growth Hormone-IGF-1 Axis: Wildtype vs. IGF-1R KO

GH Deficiency - The Short Story

  • Etiology

    • Congenital: Idiopathic (most common), genetic (e.g., GH1, GHRHR mutations), midline defects (septo-optic dysplasia).
    • Acquired: Craniopharyngioma (most common tumor), CNS radiation, trauma, infection.
  • Clinical Features

    • Neonate: Hypoglycemia, micropenis, prolonged jaundice.
    • Child: Short stature (height < -2 SD), ↓ growth velocity, delayed bone age, cherubic facies, truncal obesity, high-pitched voice.
  • Diagnosis & Treatment

    • Screening: ↓ IGF-1 & IGFBP-3.
    • Confirmation: GH stimulation tests (Insulin, Clonidine). Peak GH < 10 ng/mL is diagnostic.
    • Imaging: Pituitary MRI to identify structural causes.
    • Treatment: Recombinant Human GH (rhGH).

Child with GHD: cherubic facies, truncal obesity, MRI, X-ray

Laron Syndrome: A GH receptor defect causing GH insensitivity. Presents with features of GHD but has ↑ GH and ↓ IGF-1 levels.

GH Excess - Towering Troubles

  • Etiology: Most commonly a pituitary adenoma.
  • Clinical Manifestations:
    • Gigantism: Before epiphyseal fusion. Symmetrical overgrowth, ↑ height.
    • Acromegaly: After epiphyseal fusion. Coarse facial features, frontal bossing, prognathism, macroglossia, spade-like hands/feet.
    • Systemic: Cardiomegaly, hypertension, insulin resistance (diabetes).

Gigantism: Excess GH from macroadenoma causes rapid growth

  • Diagnosis:

Most specific test: Oral Glucose Tolerance Test (OGTT). Failure to suppress GH levels below 1 ng/mL after a 75g glucose load is diagnostic.

  • Management:
    • 1st Line: Trans-sphenoidal surgery.
    • Medical: Somatostatin analogs (Octreotide), GH receptor antagonists (Pegvisomant).

Laron Syndrome - Unresponsive Receptors

  • Pathophysiology: Autosomal recessive mutation in the Growth Hormone Receptor (GHR) gene, causing end-organ insensitivity to GH.
  • Biochemical Profile: ↑ GH, but ↓↓ IGF-1 & IGFBP-3. This paradoxical finding is key.
  • Clinical Features: Severe short stature, prominent forehead, depressed nasal bridge, small hands/feet, and hypoglycemia.
  • Treatment: Ineffective GH therapy. Requires Recombinant IGF-1 (Mecasermin).

Exam Pearl: Despite obesity, patients with Laron syndrome have a significantly lower incidence of cancer and diabetes mellitus.

Normal vs. Laron syndrome GH signaling and growth

High‑Yield Points - ⚡ Biggest Takeaways

  • GH deficiency is a key cause of pathological short stature, often with neonatal micropenis and hypoglycemia.
  • Screening involves IGF-1/IGFBP-3 levels; confirmation needs GH stimulation tests (e.g., insulin-induced hypoglycemia).
  • Laron syndrome (GH insensitivity) is a receptor defect presenting with high GH but low IGF-1.
  • GH excess causes gigantism before epiphyseal fusion and acromegaly after.
  • The most common cause of GH excess is a pituitary adenoma.

Continue reading on Oncourse

Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.

CONTINUE READING — FREE

or get the app

Rezzy — Oncourse's AI Study Mate

Have doubts about this lesson?

Ask Rezzy, your AI Study Mate, to explain anything you didn't understand

Enjoying this lesson?

Get full access to all lessons, practice questions, and more.

START FOR FREE